1例重型特发性多中心型Castleman病患者的药学监护  

Pharmaceutical care for a patient with severe idiopathic multicentric Castleman disease

作　　者：王春晖 谢风帆 吴薇 WANG Chunhui;XIE Fengfan;WU Wei(Department of Pharmacy,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Pharmacy,Mengchao Hepatobiliary Hospital,Fujian Medical University,Fuzhou 350007,China)

机构地区：[1]复旦大学附属中山医院药剂科,上海200032 [2]福建医科大学孟超肝胆医院药学部,福州350007

出　　处：《上海医药》2025年第2期81-84,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：上海市临床重点专科项目(shslczdzk06504);上海市医苑新星青年医学人才培养资助计划项目;复旦大学附属中山医院管理科学基金项目(2021ZSGL08)。

摘　　要：目的:为罕见病Castleman病患者临床合理用药提供参考。方法:临床药师参与1例重型特发性多中心型Castleman病患者治疗方案制定并提供药学监护。结果与结论:本例重型特发性多中心型Castleman病患者初始R-CHOP方案治疗效果不佳,予司妥昔单抗联合大剂量糖皮质激素治疗后疾病控制稳定,无明显不良反应和药物相互作用。临床药师凭借专业知识可为罕见病治疗保驾护航。Objective:To provide reference for the rational medication use in rare disease patients with Castleman disease.Methods:Clinical pharmacists participated in the formulation of treatment regimen and provided pharmaceutical care for a patient with severe idiopathic multicentric Castleman disease(iMCD).Results&Conclusion:The initial R-CHOP regimen had poor efficacy in this patient with severe iMCD.After treatment with siltuximab combined with high-dose glucocorticoids,the disease status was stable without obvious adverse drug reactions and drug-drug interactions.Clinical pharmacists can use their professional knowledge to escort the treatment of rare diseases.

关 键 词：CASTLEMAN病 司妥昔单抗 药学监护 

分 类 号：R973[医药卫生—药品] R551.2[医药卫生—药学]